The Top 5 Biosimilar Articles for the Week of November 16

November 20, 2020

Here are the top 5 biosimilar articles for the week of November 16, 2020.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of November 16, 2020.

Number 5: Alvotech and Cipla have joined forces to bring 5 biosimilars to treat oncology and autoimmune diseases to South Africa.

Number 4: US rheumatologists who prescribe tumor necrosis factor (TNF) inhibitors are familiar with biosimilars; however, there is broad awareness only of infliximab biosimilars, according to a survey.

Number 3: The International Generic and Biosimilar Medicines Association (IGBA) has launched the first Global Biosimilars Week, an attempt to build momentum for the use of biosimilars.

Number 2: In Europe, the pandemic has revealed problems within health care systems and the need to increase access to biosimilars and reform health care policies, according to a presentation at the Terrapinn Festival of Biologics Basel 2020.

Number 1: Results up to week 52 in the phase 3 study of Samsung Bioepis’ proposed ranibizumab biosimilar (SB11) show that primary end points were met for best corrected visual acuity and central subfield thickness.

To read all of these articles and more, visit centerforbiosimilars.com.


x